

Technical Data Sheet

Human CD137/4-1BB/TNFRSF9 (C-His)

Catalog Number: 808501, 808502
Size: 25 ug, 100 ug
Target Name: TNFRSF9, 4-1BB, CD137
Regulatory Status: RUO

Product Details


Application: ELISA, BLI
Format: Liquid, Purified
Expression Host: CHO
Species: Human
Sources: Recombinant Human CD137/4-1BB Protein (Leu24-Gln186) with C-terminus His-tag is expressed in CHO cell.
Accession Number: Q07011
Molecular Weight: The protein has a predicted molecular weight of 18.9 kDa. Under DTT-reducing conditions, it migrates at approximately 26 kDa on SDS-PAGE.
Affinity Tag: C-His
Purity: >95% based on SDS-PAGE under reducing condition
Formulation: 1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin level: Not tested
Protein Concentration: 25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and Handling: Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ -70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.

Background Information

CD137 (4-1BB) is a co-stimulatory glycoprotein from the tumor necrosis factor (TNF) receptor superfamily, expressed on activated CD4⁺ and CD8⁺ T cells. It binds to its ligand, 4-1BBL, found on antigen-presenting cells like macrophages and activated B cells. The interaction between CD137 and 4-1BBL triggers signaling through tumor necrosis factor receptor-associated factors (TRAFs), activating pathways like NF-kappaB and cytokine production. This process promotes T cell activation, proliferation, and immune responses, as well as monocyte and B-cell activation. CD137 and 4-1BBL are present in various human tumors, suggesting they may influence tumor progression. Crosslinking CD137 has shown promise in enhancing anti-tumor immunity in preclinical models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials. Additionally, soluble CD137 (sCD137) can antagonize the membrane-bound form's

function, reducing T cell proliferation and IL-2 secretion.

Product Data



Human 4-1BB Protein (C-His) on SDS-PAGE under reducing condition (P+) and non-reducing condition (P-). The gel was stained for 1 hour with BlinkBlue (catalog 700102). The purity of this protein appears to be greater than 95%.